Husted Steen Elkjaer, Nielsen Hans Kraemmer
Medicinsk-kardiologisk Afdeling, Århus Sygehus, Århus Universitetshospital, 8000 Århus C, Denmark.
Ugeskr Laeger. 2010 Oct 18;172(42):2888-91.
In aspirin-treated patients with acute coronary syndromes without ST-segment elevation unfractionated heparin (UFH) or low molecular weight heparin (LMWH) treatment < 7 days significantly reduce the risk of acute myocardial infarction (AMI), and LMWH furthermore reduces revascularisation. There is a non-significant effect on mortality compared with placebo and an insignificantly increased risk of haemorrhagic complications. No net clinical benefit of LMWH was found compared to UHF, but LMWH has pharmacokinetic advantages. The optimal duration of heparin treatment remains controversial.
在接受阿司匹林治疗的非ST段抬高型急性冠脉综合征患者中，使用普通肝素（UFH）或低分子量肝素（LMWH）治疗少于7天可显著降低急性心肌梗死（AMI）风险，而且LMWH还可减少血运重建。与安慰剂相比，对死亡率的影响不显著，出血并发症风险虽有增加但不显著。与UFH相比，未发现LMWH有净临床获益，但LMWH具有药代动力学优势。肝素治疗的最佳持续时间仍存在争议。
